List view / Grid view
6 June 2016 | By Victoria White, Digital Content Producer
We recently caught up with Dr Jörg Barth, Boehringer Ingelheim, to find out more about the company’s oncology pipeline and presence at ASCO....
18 May 2016 | By Katie Sadler
New data has revealed tiotropium improves lung function in children who continue to experience asthma symptoms despite taking other maintenance therapies.
19 April 2016 | By Victoria White, Digital Content Producer
Boehringer Ingelheim and Lilly have announced plans to conduct two trials investigating Jardiance for the treatment of people with chronic heart failure...
13 April 2016 | By Victoria White, Digital Content Producer
Results from the Phase IIb LUX-Lung 7 trial showed that afatinib significantly reduced the risk of lung cancer progression by 27% versus gefitinib...
8 April 2016 | By Victoria White, Digital Content Producer
A new study shows that levels of eosinophils can help identify patients with COPD who may and may not benefit from the addition of ICS treatment...
7 April 2016 | By Victoria White, Digital Content Producer
Afatinib is approved for the treatment of patients whose disease has progressed on or after treatment with platinum-based chemotherapy...
8 March 2016 | By Victoria White
The addition of Spiriva Respimat to other asthma maintenance therapies helps improve asthma symptom control regardless of allergy subtype...
7 March 2016 | By Victoria White
BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma...
29 February 2016 | By Victoria White
The CHMP positive opinion is based on the results of the head-to-head LUX-Lung 8 trial in patients with SqCC...
29 February 2016 | By Victoria White
Boehringer Ingelheim's new initiatives are dedicated to raising awareness of IPF, a rare disease that is frequently misdiagnosed and little understood...
25 February 2016 | By Victoria White
Pooled analysis from the TOMORROW and INPULSIS trials provides further evidence that Ofev (nintedanib) significantly reduces the risk of acute exacerbations by 47% in people...
17 February 2016 | By Victoria White
Praxbind (idarucizumab) is now available to be used commercially after the Health Technology Appraisal bodies agreed that it is eligible for full reimbursment without the need for a full appraisal.
4 February 2016 | By Victoria White
Unlike other asthma daily maintenance treatments, Spiriva Respimat is from a new class of medications in asthma known as long-acting anticholinergics...
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
27 January 2016 | By Victoria White
Results from the LUX-Lung 7 trial demonstrated superiority in progression-free survival and time to treatment failure with Boehringer Ingelheim’s Giotrif/Gilotrif (afatinib) versus Iressa (gefitinib)...
